Associated Papers
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.
Brown JR et al.
Blood, 2026
Ancestry-dependent patterns of somatic mosaicism and clonal hematopoiesis mutations in over 125,000 individuals reveal distinct cancer associations.
Colin-Leitzinger C et al.
Human Genomics, 2025
Clinical Validation of a Rapid Automated Lymphoma Next-Generation Sequencing Panel.
Krigstein M et al.
Annals of Laboratory Medicine, 2025
Genes-first and phenotypes-first paths to treatment resistance in hematological malignancies.
Tamellini E et al.
Cell Death & Disease, 2025
Structural insights into chemoresistance mutants of BCL-2 and their targeting by stapled BAD BH3 helices.
DeAngelo TM et al.
Nature Communications, 2025
Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice.
Blombery P et al.
Leukemia, 2025
Distinct characteristics of lymphoid and myeloid clonal hematopoiesis in World Trade Center first responders.
Esai Selvan M et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Clonal hematopoiesis is associated with distinct rheumatoid arthritis phenotypes.
Hiitola E et al.
Science Advances, 2025
Peripheral blood somatic mosaicism and clonal hematopoiesis across ancestry backgrounds.
Colin-Leitzinger C et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Recent Advances in the Molecular Biology of Chronic Lymphocytic Leukemia: How to Define Prognosis and Guide Treatment.
Arcari A et al.
Cancers, 2024
Comprehensive Genomic Profiling in Non-Myeloid Hematologic Malignancies Identifies Variants That Can Alter Clinical Practice.
Lin C et al.
Hematology Reports, 2024
Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib.
Aslan B et al.
Blood Advances, 2024
Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2.
Guo Y et al.
Journal of Medicinal Chemistry, 2024
Predictive and prognostic molecular biomarkers in lymphomas.
Iorgulescu JB et al.
Pathology, 2024
Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax.
Jain N et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
Integrative genomic analyses combined with molecular dynamics simulations reveal the impact of deleterious mutations of Bcl-2 gene on the apoptotic machinery and implications in carcinogenesis.
Elamin G et al.
Frontiers in Genetics, 2024
All-CLL: A Capture-based Next-generation Sequencing Panel for the Molecular Characterization of Chronic Lymphocytic Leukemia.
López-Oreja I et al.
Hemasphere, 2023
Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples.
Khalsa JK et al.
Blood, 2023
Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax.
Kotmayer L et al.
International Journal of Molecular Sciences, 2023
Emerging Therapies in CLL in the Era of Precision Medicine.
Iyer P et al.
Cancers, 2023
Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia.
Moujalled DM et al.
Blood, 2023
Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies.
Thomalla D et al.
Blood, 2022
Precision diagnostics in lymphomas - Recent developments and future directions.
Mansouri L et al.
Seminars in Cancer Biology, 2022
Are we finally getting personal? Moving towards a personalized approach in chronic lymphocytic leukemia.
Albi E et al.
Seminars in Cancer Biology, 2022
Real-world management of targeted therapies in chronic lymphocytic leukemia.
Weis TM et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners, 2022
Benchmarking of SpCas9 variants enables deeper base editor screens of BRCA1 and BCL2.
Sangree AK et al.
Nature Communications, 2022
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.
Blombery P et al.
Blood, 2022
Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
Gángó A et al.
Pathology, 2022
Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors.
Thompson ER et al.
Blood Advances, 2022
Comprehensive characterization of single-cell full-length isoforms in human and mouse with long-read sequencing.
Tian L et al.
Genome Biology, 2021
Genomics of Resistance to Targeted Therapies.
Thangavadivel S et al.
Hematology/oncology Clinics of North America, 2021
The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment.
Pérez-Carretero C et al.
Diagnostics (basel, Switzerland), 2021
Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center study.
Sutton LA et al.
Haematologica, 2021
Case Report: Multiple Chromosomal Translocations Including Novel CIITA-CREBBP Fusion and Mutations in a Follicular Lymphoma.
Wang HY et al.
Frontiers in Oncology, 2021
SOHO State of the Art Updates and Next Questions: Clonal Evolution in Chronic Lymphocytic Leukemia.
Condoluci A et al.
Clinical Lymphoma, Myeloma & Leukemia, 2020
Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.
Lucas F et al.
Blood, 2020
Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.
Zhao S et al.
American Journal of Hematology, 2020
An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy.
Cohen JA et al.
Cancers, 2020
The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome.
Brieghel C et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2020
An update on: molecular genetics of high-risk chronic lymphocytic leukemia.
Moia R et al.
Expert Review of Hematology, 2020